US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Morgan Stanley analyst Terence Flynn has maintained their bearish stance on BMY stock, giving a Sell rating on September 3. Terence Flynn has ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...